Astellas, seagen and merck announce results of clinical trial investigating padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) and padcev as monotherapy in first-line advanced urothelial cancer

– results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab –  – data highlighted in late-breaking presentation at the european society for medical oncology (esmo) congress 2022 – tokyo and bothell, wash. and rahway, n.j.
SGEN Ratings Summary
SGEN Quant Ranking